17 results on '"Luft, Thomas"'
Search Results
2. Contributors
- Author
-
Adorini, Luciano, primary, Albert, Matthew L., additional, Allavena, Paola, additional, Aloisi, Francesca, additional, Amigorena, Sebastian, additional, André, Fabrice, additional, Austyn, Jonathan M., additional, Banchereau, Jacques, additional, Bedford, Penelope A., additional, Stolz, Donna Beer, additional, Bhardwaj, Nina, additional, Black, C. Allen, additional, Bobryshev, Yuri V., additional, Brière, Francine, additional, Borvak, Jozef, additional, Caux, Christophe, additional, Cebon, Jonathan, additional, Cicinnati, Vito R., additional, Citterio, S., additional, Clark, Georgina J., additional, Cochand, L., additional, Cabezas, Sandra Columba, additional, Curiel, Tyler J., additional, Davis, Ian, additional, Demetris, Anthony J., additional, Dong, Xin, additional, Dubois, Bertrand, additional, Falo, Louis D., additional, Fan, Lian, additional, Fayette, Jerome, additional, Fernandez, Nadine C., additional, Frank, I., additional, Frankel, S. Schlesinger, additional, Fong, Lawrence, additional, Fonteneau, Jean-François, additional, Forrester, John V., additional, Fung, John J., additional, Gajewski, Thomas F., additional, Galy, Anne, additional, Gambotto, Andrea, additional, Garrett, Wendy S., additional, Granelli-Piperno, Angela, additional, Granucci, F., additional, Gudin, A.M., additional, Hart, Derek N.J., additional, Holgate, S.T., additional, Holloway, J.A., additional, Huang, Fang-Ping, additional, Ignatius, R., additional, Isaeva, Tatyana, additional, Jaffe, Ronald, additional, Kadowaki, Nori, additional, Kalinski, Pawel, additional, Kapsenberg, Martien L., additional, Kikly, Kristine, additional, Knight, Stella C., additional, Kosco-Vilbois, Marie H., additional, Larregina, Adriana T., additional, Larsson, Marie, additional, Lee, Andrew, additional, Liu, Li Ming, additional, Liu, Yong-Jun, additional, Lo, David, additional, Lotze, Michael T., additional, Lu, Lina, additional, Luft, Thomas, additional, MacDonald, Kelli, additional, MacPherson, G. Gordon, additional, Manning, Thomas C., additional, Mantovani, Alberto, additional, Maraskovsky, Eugene, additional, Marches, Florentina, additional, Masurier, Carole, additional, Matsue, Hiroyuki, additional, Maurer, Dieter, additional, McMenamin, Paul G., additional, Mellman, Ira, additional, Messmer, D., additional, Murphey-Corb, Michael, additional, Murase, Noriko, additional, Nicod, Laurent P., additional, Norris, Karen A., additional, O'Connell, Peta J., additional, Papworth, Glenn D., additional, Palucka, Karolina, additional, Pope, Melissa, additional, Pulendran, Bali, additional, Racz, Paul, additional, Randolph, Gwendalyn J., additional, Raposo, Graça, additional, Redmond, Will, additional, Regnault, Armelle, additional, Reilly, Christina R., additional, Rescigno, M., additional, Castagnoli, Paola Ricciardi, additional, Rittig, M., additional, Robbins, Paul D., additional, Salter, Russell D., additional, Semper, Amanda E., additional, Serafini, Barbara, additional, Soumelis, Vassili, additional, Sozzani, Silvano, additional, Spits, Hergen, additional, Stahl-Hennig, C., additional, Steinman, Ralph M., additional, Steptoe, Raymond J., additional, Stingl, Georg, additional, Takashima, Akira, additional, Tenner-Racz, K., additional, Terme, Magali, additional, Théry, Clotilde, additional, Thomas, Ranjeny, additional, Thomson, Angus W., additional, Urbano, M., additional, Valzasina, B., additional, Vandenabeele, Stephane, additional, Vuckovic, Slavica, additional, Watkins, Simon C., additional, Wei, Shuang, additional, Weber, Jeffrey, additional, Wilson, Cara C., additional, Wolfers, Joseph, additional, Wu, Li, additional, Zhong, L., additional, Zitvogel, Laurence, additional, and Zou, Weiping, additional
- Published
- 2001
- Full Text
- View/download PDF
3. Hope for Motherhood: Pregnancy After Allogeneic Hematopoietic Cell Transplantation - a National Multicenter Study.
- Author
-
Sockel K, Neu A, Goeckenjan M, Ditschkowski M, Hilgendorf I, Kroeger N, Ayuk FA, Stölzel F, Middeke JM, Eder M, Bethge WA, Finke J, Bertz H, Kobbe G, Kaufmann M, Platzbecker U, Beverungen D, Schmid C, von Bonin M, Egger-Heidrich K, Heberling L, Trautmann-Grill K, Teipel R, Bug G, Tischer J, Fraccaroli A, Fante MA, Wolff D, Luft T, Winkler J, Schäfer-Eckart K, Scheid C, Holtick U, Klein S, Blau I, Burchert A, Wulf GG, Hasenkamp J, Schwerdtfeger R, Kaun S, Junghanss C, Wortmann F Dr. med, Winter S, Neidlinger H, Theuser C, Beyersmann J, Bornhäuser M, Schmeller S, and Schetelig J
- Abstract
Improved long-term survival rates after allogeneic hematopoietic cell transplantation (alloHCT) make family planning for young adult cancer survivors an important topic. However, treatment-related infertility risk poses challenges. To assess pregnancy and birth rates in a contemporary cohort, we conducted a national multicenter study using data from the German Transplant Registry, focusing on adult women aged 18-40 who underwent alloHCT between 2003 and 2018. Out of 2,654 transplanted women, 50 women experienced 74 pregnancies, occurring at a median of 4.7 years post-transplant. Fifty-seven of these resulted in live births (77%). The annual first birth rate among HCT recipients was 0.45% (95%CI: 0.31 - 0.59%), which is more than six times lower than in the general population. The probability of a live birth 10 years after HCT was 3.4 % (95%CI: 2.3- 4.5%). Factors associated with an increased likelihood of pregnancy were younger age at alloHCT, non-malignant transplant indications, no total-body-irradiation (TBI) or a cumulative dose of <8 Gray, and non-myeloablative/reduced-intensity conditioning. 72% of pregnancies occurred spontaneously, with assisted reproductive technologies (ART) used in the remaining cases. Preterm delivery and low birth weight were more common than in the general population. This study represents the largest dataset reporting pregnancies in a cohort of adult female alloHCT recipients. Our findings underscore a meaningful chance of pregnancy in alloHCT recipients. ART techniques are important and funding should be made available. However, the potential for spontaneous pregnancies should not be underestimated, and patients should be informed of the possibility of unexpected pregnancy despite reduced fertility. Further research is warranted to understand the impact of conditioning decisions on fertility preservation., (Copyright © 2024 American Society of Hematology.)
- Published
- 2024
- Full Text
- View/download PDF
4. The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature.
- Author
-
Mathioudaki A, Wang X, Sedloev D, Huth R, Kamal A, Hundemer M, Liu Y, Vasileiou S, Lulla P, Müller-Tidow C, Dreger P, Luft T, Sauer T, Schmitt M, Zaugg JB, and Pabst C
- Subjects
- Humans, Bone Marrow pathology, CD8-Positive T-Lymphocytes pathology, Recurrence, Leukemia, Myeloid, Acute therapy, Leukemia, Myeloid, Acute drug therapy, Hematopoietic Stem Cell Transplantation
- Abstract
Abstract: Acute myeloid leukemia (AML) is a hematologic malignancy for which allogeneic hematopoietic cell transplantation (allo-HCT) often remains the only curative therapeutic approach. However, incapability of T cells to recognize and eliminate residual leukemia stem cells might lead to an insufficient graft-versus-leukemia (GVL) effect and relapse. Here, we performed single-cell RNA-sequencing (scRNA-seq) on bone marrow (BM) T lymphocytes and CD34+ cells of 6 patients with AML 100 days after allo-HCT to identify T-cell signatures associated with either imminent relapse (REL) or durable complete remission (CR). We observed a higher frequency of cytotoxic CD8+ effector and gamma delta (γδ) T cells in CR vs REL samples. Pseudotime and gene regulatory network analyses revealed that CR CD8+ T cells were more advanced in maturation and had a stronger cytotoxicity signature, whereas REL samples were characterized by inflammatory tumor necrosis factor/NF-κB signaling and an immunosuppressive milieu. We identified ADGRG1/GPR56 as a surface marker enriched in CR CD8+ T cells and confirmed in a CD33-directed chimeric antigen receptor T cell/AML coculture model that GPR56 becomes upregulated on T cells upon antigen encounter and elimination of AML cells. We show that GPR56 continuously increases at the protein level on CD8+ T cells after allo-HCT and confirm faster interferon gamma (IFN-γ) secretion upon re-exposure to matched, but not unmatched, recipient AML cells in the GPR56+ vs GPR56- CD8+ T-cell fraction. Together, our data provide a single-cell reference map of BM-derived T cells after allo-HCT and propose GPR56 expression dynamics as a surrogate for antigen encounter after allo-HCT., (© 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
5. IFNγ Causes Keratinocyte Necroptosis in Acute Graft-Versus-Host Disease.
- Author
-
Freund L, Oehrl S, Schwingen J, Haeberle S, Döbel T, Lee PDH, Meisel S, Mihalceanu S, Rußwurm M, Luft T, and Schäkel K
- Subjects
- Mice, Humans, Animals, Apoptosis, Cell Death, Keratinocytes metabolism, Inflammation metabolism, Dermatitis, Graft vs Host Disease
- Abstract
Epidermal keratinocytes form the first-line cellular barrier of the skin for protection against external injuries and maintenance of local tissue homeostasis. Expression of ZBP1 was shown to cause necroptotic keratinocyte cell death and skin inflammation in mice. We sought to characterize the relevance of ZBP1 and necroptosis in human keratinocytes and type 1-driven cutaneous acute graft-versus-host disease. in this study, we identify ZBP1 expression, necroptosis, and interface dermatitis as being the hallmarks of acute graft-versus-host disease. ZBP1 expression was dependent on leukocyte-derived IFNγ, and interference with IFNγ signaling by Jak inhibition prevented cell death. In predominantly IL-17-driven psoriasis, both ZBP1 expression and necroptosis could not be detected. Of note, in contrast to the signaling in mice, ZBP1 signaling in human keratinocytes was not affected by RIPK1's presence. These findings show that ZBP1 drives inflammation in IFNγ-dominant type 1 immune responses in human skin and may further point to a general role of ZBP1-mediated necroptosis., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
6. Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells.
- Author
-
Ni M, Wang L, Ding Y, Gong W, Wang S, Neuber B, Schubert ML, Sauer T, Hückelhoven-Krauss A, Luft T, Hegenbart U, Schönland S, Eckstein V, Wang J, Krüger W, Müller-Tidow C, Dreger P, Schmitt M, and Schmitt A
- Subjects
- CD8-Positive T-Lymphocytes, Chronic Disease, Hepatitis A Virus Cellular Receptor 2, Humans, Steroids therapeutic use, T Follicular Helper Cells, Up-Regulation, Graft vs Host Disease, Photopheresis
- Abstract
Extracorporeal photopheresis (ECP), a personalized cellular immunotherapy, constitutes a promising treatment for steroid-refractory/-resistant graft-versus-host disease (SR-GvHD), with encouraging clinical response rates. To further investigate its mechanism of action, ECP's effects on T helper (Th) cells as well as on expression of immune checkpoint (PD-1 and Tim-3) and apoptotic (Fas receptor [FasR]) molecules were investigated in 27 patients with SR-GvHD. Our data show that GvHD patients had significantly higher levels of Th2, Th17, Th22 and granulocyte-macrophage colony-stimulating factor (GM-CSF)-positive Th (ThG) cells and clearly lower levels of T follicular helper (Tfh) cells, including Th1- and Th2-like cells, compared with healthy donors. ECP therapy for GvHD was effective through the modulation of different Th subsets: increases of Th22 (1.52-fold) and Tfh cells (1.48-fold) in acute GvHD (aGvHD) and increases of Th2-like Tfh cells (1.74-fold) in chronic GvHD (cGvHD) patients were associated with clinical response. Expression of FasR was further upregulated in CD4
+ CD8+ T cells. Additionally, Tim-3-expressing effector T cells associated with the severity of GvHD were reduced. Taken together, these data show that ECP therapy exerts immunomodulatory effects by promoting a balanced immune reconstitution and inducing immune tolerance. Therefore it represents an attractive option for the treatment of GvHD., Competing Interests: Conflict of Interest The authors declare no competing financial interests, except the following: Funding was provided by Mallinckrodt to AS and MS for the documentation of the clinical course and for the analysis of patient immune cells; MS received funding for collaborative research from Apogenix, Hexal and Novartis and travel grants from Hexal and Kite; he received financial support for educational activities and conferences from bluebird bio, Kite and Novartis; he is a board member for MSD and (co-)PI of clinical trials of MSD, GSK, Kite and BMS. AS received travel grants from Hexal and Jazz Pharmaceuticals. MS and AS are co-founders and shareholders of TolerogenixX Ltd. AS and LW are part-time and full-time employees, respectively, of TolerogenixX Ltd., (Copyright © 2021 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
7. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
- Author
-
Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, Sanchi A, Radujkovic A, Horn P, Dolatshad H, Roy S, Broxholme J, Lockstone H, Taylor S, Giagounidis A, Vyas P, Schuh A, Hamblin A, Papaemmanuil E, Killick S, Malcovati L, Hennrich ML, Gavin AC, Ho AD, Luft T, Hellström-Lindberg E, Cazzola M, Smith CWJ, Smith S, and Boultwood J
- Subjects
- Cohort Studies, DNA Repair, Gene Expression Regulation, Humans, Myelodysplastic Syndromes epidemiology, Phosphoproteins genetics, Serine-Arginine Splicing Factors genetics, Splicing Factor U2AF genetics, Survival Analysis, Mutation, Myelodysplastic Syndromes genetics, RNA Splicing, RNA Splicing Factors genetics, Spliceosomes genetics
- Abstract
SF3B1 , SRSF2 , and U2AF1 are the most frequently mutated splicing factor genes in the myelodysplastic syndromes (MDS). We have performed a comprehensive and systematic analysis to determine the effect of these commonly mutated splicing factors on pre-mRNA splicing in the bone marrow stem/progenitor cells and in the erythroid and myeloid precursors in splicing factor mutant MDS. Using RNA-seq, we determined the aberrantly spliced genes and dysregulated pathways in CD34
+ cells of 84 patients with MDS. Splicing factor mutations result in different alterations in splicing and largely affect different genes, but these converge in common dysregulated pathways and cellular processes, focused on RNA splicing, protein synthesis, and mitochondrial dysfunction, suggesting common mechanisms of action in MDS. Many of these dysregulated pathways and cellular processes can be linked to the known disease pathophysiology associated with splicing factor mutations in MDS, whereas several others have not been previously associated with MDS, such as sirtuin signaling. We identified aberrantly spliced events associated with clinical variables, and isoforms that independently predict survival in MDS and implicate dysregulation of focal adhesion and extracellular exosomes as drivers of poor survival. Aberrantly spliced genes and dysregulated pathways were identified in the MDS-affected lineages in splicing factor mutant MDS. Functional studies demonstrated that knockdown of the mitosis regulators SEPT2 and AKAP8, aberrantly spliced target genes of SF3B1 and SRSF2 mutations, respectively, led to impaired erythroid cell growth and differentiation. This study illuminates the effect of the common spliceosome mutations on the MDS phenotype and provides novel insights into disease pathophysiology., (© 2018 by The American Society of Hematology.)- Published
- 2018
- Full Text
- View/download PDF
8. Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia.
- Author
-
Radujkovic A, Schnitzler P, Ho AD, Dreger P, and Luft T
- Subjects
- Adult, Aged, Aged, 80 and over, Calcitriol analogs & derivatives, Calcitriol pharmacology, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Leukemia, Myeloid, Acute blood, Male, Middle Aged, Myelodysplastic Syndromes blood, Retrospective Studies, Treatment Outcome, Vitamin D administration & dosage, Vitamin D antagonists & inhibitors, Azacitidine therapeutic use, Leukemia, Myeloid, Acute drug therapy, Myelodysplastic Syndromes drug therapy, Vitamin D blood
- Abstract
Background & Aims: Azacitidine (AZA) therapy has become the recommended first-line treatment for patients with high-risk myelodysplastic syndromes (MDS) and oligoblastic (<30% bone marrow blasts) acute myeloid leukemia (AML). However, improvement of the efficacy of AZA treatment remains a challenge. We retrospectively tested the hypothesis that VitD levels (25-hydroxyvitamin D3) prior to start of first-line AZA therapy are predictive of overall survival (OS) in patients diagnosed with MDS and secondary oligoblastic AML. Furthermore, the antiproliferative effects of AZA in combination with 25-hydroxyvitamin D3 and 1α,25-dihydroxyvitamin D3 were investigated in vitro., Methods: A total of 58 patients treated at our center between 2006 and 2014 were analyzed. Serum levels of VitD were quantified using a standard, commercially available 25-hydroxyvitamin D3 chemiluminescent immunoassay. Effects on cell proliferation were assessed using tetrazolium-based MTT assays., Results: Median serum VitD level prior to AZA treatment was 32.8 nM (range 11.0-101.5 nM). Patient, disease and treatment characteristics did not differ significantly between the low (≤32.8 nM; n = 29) and high (>32.8 nM; n = 29) VitD group. Estimated probability of 2-year OS in the low versus high VitD group was 14% versus 40% (P < 0.05). In multivariable analysis with OS as endpoint, adverse cytogenetics (HR 2.66, P = 0.03) and VitD (per 10 nM decrease, HR 1.68, P = 0.02) were independent predictors of worse survival. In-vitro treatment of myeloid cell lines with AZA in combination with VitD produced synergistic and additive antiproliferative effects. Addition of nanomolar VitD concentrations to AZA resulted in potentiation of AZA activity. Conversely, combination with the VitD antagonist TEI-9647 resulted in inhibition of AZA activity., Conclusions: Our study suggests that higher VitD levels were associated with a survival advantage following first-line AZA therapy. Enhanced cytotoxic effects upon combination treatment may contribute to the observed clinical effects. VitD repletion/supplementation during AZA treatment should be explored., (Copyright © 2016 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
9. Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta.
- Author
-
Hermanrud C, Ryner M, Luft T, Jensen PE, Ingenhoven K, Rat D, Deisenhammer F, Sørensen PS, Pallardy M, Sikkema D, Bertotti E, Kramer D, Creeke P, and Fogdell-Hahn A
- Subjects
- Biological Assay, Cell Line, Tumor, Enzyme-Linked Immunosorbent Assay, Humans, Luciferases, Multiple Sclerosis drug therapy, Multiple Sclerosis immunology, Neutralization Tests, Sensitivity and Specificity, Antibodies, Neutralizing blood, Genes, Reporter, Interferon-beta immunology
- Abstract
Neutralizing anti-drug antibodies (NAbs) against therapeutic interferon beta (IFNβ) in people with multiple sclerosis (MS) are measured with cell-based bioassays. The aim of this study was to redevelop and validate two luciferase reporter-gene bioassays, LUC and iLite, using a cut-point approach to identify NAb positive samples. Such an approach is favored by the pharmaceutical industry and governmental regulatory agencies as it has a clear statistical basis and overcomes the limitations of the current assays based on the Kawade principle. The work was conducted following the latest assay guidelines. The assays were re-developed and validated as part of the "Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk" (ABIRISK) consortium and involved a joint collaboration between four academic laboratories and two pharmaceutical companies. The LUC assay was validated at Innsbruck Medical University (LUCIMU) and at Rigshospitalet (LUCRH) Copenhagen, and the iLite assay at Karolinska Institutet, Stockholm. For both assays, the optimal serum sample concentration in relation to sensitivity and recovery was 2.5% (v/v) in assay media. A Shapiro-Wilk test indicated a normal distribution for the majority of runs, allowing a parametric approach for cut-point calculation to be used, where NAb positive samples could be identified with 95% confidence. An analysis of means and variances indicated that a floating cut-point should be used for all assays. The assays demonstrated acceptable sensitivity for being cell-based assays, with a confirmed limit of detection in neat serum of 1519 ng/mL for LUCIMU, 814 ng/mL for LUCRH, and 320 ng/mL for iLite. Use of the validated cut-point assay, in comparison with the previously used Kawade method, identified 14% more NAb positive samples. In conclusion, implementation of the cut-point design resulted in increased sensitivity to detect NAbs. However, the clinical significance of these low positive titers needs to be further evaluated., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
10. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system.
- Author
-
Luft T, Dietrich S, Falk C, Conzelmann M, Hess M, Benner A, Neumann F, Isermann B, Hegenbart U, Ho AD, and Dreger P
- Subjects
- Adult, Angiopoietin-2 blood, Angiopoietin-2 immunology, Chemokine CCL26, Chemokine CX3CL1 blood, Chemokine CX3CL1 immunology, Chemokine CXCL5 blood, Chemokine CXCL5 immunology, Chemokines, CC blood, Chemokines, CC immunology, Drug Resistance, Endothelium, Vascular immunology, Enzyme-Linked Immunosorbent Assay, Fas Ligand Protein blood, Fas Ligand Protein immunology, Female, Graft vs Host Disease etiology, Graft vs Host Disease immunology, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Logistic Models, Male, Middle Aged, Steroids immunology, Survival Analysis, T-Lymphocytes immunology, TNF-Related Apoptosis-Inducing Ligand blood, TNF-Related Apoptosis-Inducing Ligand immunology, Thrombomodulin blood, Thrombomodulin immunology, Transplantation, Homologous, Vascular Endothelial Growth Factor A blood, Vascular Endothelial Growth Factor A immunology, Young Adult, Endothelium, Vascular metabolism, Graft vs Host Disease drug therapy, Hematopoietic Stem Cell Transplantation methods, Steroids therapeutic use, T-Lymphocytes metabolism
- Abstract
Acute graft-versus-host disease (GVHD) is a major complication of allogeneic stem cell transplantation (SCT) and can be readily controlled by systemic high-dose steroids in many patients. However, patients whose GVHD is refractory to this therapy have a poor prognosis. Refractory patients have ongoing end-organ damage despite effective immunosuppression with second-line regimens, suggesting pathomechanisms independent from the initiating T-cell attack. To explore whether endothelial damage might contribute to GVHD refractoriness and to study the role of angiopoietin-2 (ANG2) in this process, we have compared kinetics of T-cell activation markers and markers of endothelial dysfunction in the serum of patients with sensitive (n = 23) and refractory GVHD (n = 25). Longitudinal measurements of soluble FAS ligand along with other immune markers demonstrate that refractory patients are not exposed to an overwhelming or unresponsive T-cell attack. However, in contrast to sensitive GVHD, refractory GVHD was associated with rising thrombomodulin levels and high ANG2/ vascular endothelial-derived growth factor ratios. Patients with refractory GVHD showed significantly increased ANG2 levels already before SCT. These results suggest that endothelial cell vulnerability and dysfunction, rather than refractory T-cell activity, drives treatment refractoriness of GVHD and opens new avenues for prediction and control of this devastating condition.
- Published
- 2011
- Full Text
- View/download PDF
11. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease.
- Author
-
Luft T, Conzelmann M, Benner A, Rieger M, Hess M, Strohhaecker U, Görner M, Hegenbart U, Ho AD, and Dreger P
- Subjects
- Adolescent, Adult, Aged, Biomarkers blood, Diagnosis, Differential, Drug Monitoring methods, Female, Graft vs Host Disease drug therapy, Humans, Immunosuppressive Agents therapeutic use, Intestinal Diseases diagnosis, Liver Diseases diagnosis, Male, Middle Aged, Severity of Illness Index, Apoptosis, Epithelial Cells cytology, Graft vs Host Disease diagnosis, Keratin-18 blood, Peptide Fragments blood
- Abstract
Graft-versus-host disease (GVHD) is the main complication of allogeneic stem cell transplantation. However, diagnosis of GVHD and evaluation of response to immunosuppressive treatment is sometimes difficult. Since apoptosis is the histopathologic hallmark in GVHD, we investigated whether active GVHD-induced target organ destruction is mirrored by serum levels of the caspase-cleaved neo-epitope of cytokeratin-18 fragments (CK18Fs). Serum CK18F kinetics was monitored by M30 antibody-based enzyme-linked immunosorbent assay (ELISA) in 50 patients who fulfilled histopathologic and/or clinical criteria diagnostic for GVHD. Both intestinal and hepatic GVHD were consistently associated with significant elevations of CK18F levels over baseline. Responses of GVHD to immunosuppressive therapy were paralleled by CK18F decreases, whereas resistant GVHD was characterized by persistent CK18F rises. Clinical conditions that might represent relevant differential diagnoses, such as toxic mucositis, noncomplicated, infection-related diarrhea, and veno-occlusive disease were not associated with CK18F elevations. In conclusion, CK18F monitoring provides a serum marker for quantitative assessment of GVHD-associated apoptotic activity in intestinal and hepatic GVHD. Although apoptosis is not GVHD-specific, CK18Fs may help to distinguish active GVHD from GVHD-unrelated conditions with similar symptoms, and to monitor response to immunosuppressive treatment. Prospective studies are warranted to evaluate how CK18Fs may assist in the diagnosis, grading, and treatment guidance of GVHD.
- Published
- 2007
- Full Text
- View/download PDF
12. GSK-3 mediates differentiation and activation of proinflammatory dendritic cells.
- Author
-
Rodionova E, Conzelmann M, Maraskovsky E, Hess M, Kirsch M, Giese T, Ho AD, Zöller M, Dreger P, and Luft T
- Subjects
- Cells, Cultured, Humans, Interleukin-12 genetics, Interleukins genetics, Macrophages cytology, Proto-Oncogene Proteins c-akt physiology, Transcription, Genetic, Tumor Necrosis Factor-alpha genetics, Cell Differentiation immunology, Dendritic Cells immunology, Glycogen Synthase Kinase 3 physiology, Inflammation immunology
- Abstract
The key components of the intracellular molecular network required for the expression of a specific function of dendritic cells (DCs) are as yet undefined. Using an in vitro model of human monocyte-derived DC differentiation, this study investigates the role of glycogen synthase kinase 3 (GSK-3), a multifunctional enzyme critical for cellular differentiation, apoptosis, self-renewal, and motility, in this context. We demonstrate that GSK-3 (1) inhibits macrophage development during differentiation of DCs, (2) is constitutively active in immature DCs and suppresses spontaneous maturation, and (3) acquires a proinflammatory functional status mediating high levels of IL-12, IL-6, and TNF-alpha secretion, and partially inhibits IL-10 in the context of DC activation. In particular, GSK-3 enhances IL-12p35 mRNA expression and thus the production of the proinflammatory cytokine IL-12p70 by integrating the activities of other kinases priming GSK-3 targets and the inhibitory effects of Akt-1. GSK-3 may therefore act as a key integrator of activating and inhibitory pathways involved in proinflammatory DC differentiation and activation.
- Published
- 2007
- Full Text
- View/download PDF
13. Adaptive functional differentiation of dendritic cells: integrating the network of extra- and intracellular signals.
- Author
-
Luft T, Rodionova E, Maraskovsky E, Kirsch M, Hess M, Buchholtz C, Goerner M, Schnurr M, Skoda R, and Ho AD
- Subjects
- Cells, Cultured, Cyclic AMP immunology, Cytokines immunology, Dendritic Cells cytology, Humans, Mitogen-Activated Protein Kinase 1 immunology, Mitogen-Activated Protein Kinase 3 immunology, Oncogene Protein v-akt immunology, Phosphatidylinositol 3-Kinases immunology, Type C Phospholipases immunology, p38 Mitogen-Activated Protein Kinases immunology, Cell Differentiation immunology, Cell Movement immunology, Dendritic Cells immunology, Signal Transduction immunology
- Abstract
Phenotypic maturation, cytokine secretion, and migration are distinct functional characteristics of dendritic cells (DCs). These functions are independently regulated by a number of extracellular variables, such as type, strength, and persistence of an array of soluble and membrane-bound mediators. Since the exact composition of these variables in response to infection may differ between individuals, the intracellular signaling pathways activated by these extracellular networks may more closely correlate with DC function and predict the course of adaptive immunity. We found that activation of p38 kinase (p38K), extracellular signal-related kinase 1/2 (ERK1/2), and phosphatidylcholine-specific phospholipase C (PC-PLC) enhanced cytokine secretion, whereas p38K, cyclic adenosine monophosphate (cAMP), and PC-PLC enhanced migration. In contrast, phosphatidylinositol 3-kinase (PI3K)/Akt-1 and cAMP inhibited cytokine secretion while ERK1/2 inhibited migration. Migration and cytokine secretion further differed in their sensitivity to inhibition over time. However, although DCs could be manipulated to express migration, cytokine secretion, or both, the level of activation or persistence of intracellular pathway signaling was not predictive. Our results suggest a modular organization of function. We hypothesize that the expression of specific DC functions integrates a large variety of activating and inhibitory variables, and is represented by the formation of a functional unit of molecular networks-the signal response module (SRM). The combined activities of these modules define the functional outcome of DC activation.
- Published
- 2006
- Full Text
- View/download PDF
14. Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells.
- Author
-
Luft T, Maraskovsky E, Schnurr M, Knebel K, Kirsch M, Görner M, Skoda R, Ho AD, Nawroth P, and Bierhaus A
- Subjects
- CD40 Antigens physiology, CD40 Ligand pharmacology, Chemokine CCL22, Chemokines, CC physiology, Chemotaxis, Cytokines metabolism, Dendritic Cells metabolism, Dendritic Cells physiology, Escherichia coli physiology, Humans, Interleukin-12 metabolism, Mitogen-Activated Protein Kinases metabolism, Monocytes cytology, NF-kappa B metabolism, Protein Subunits metabolism, p38 Mitogen-Activated Protein Kinases metabolism, CD40 Antigens metabolism, Dendritic Cells immunology, Immunity, Cellular, Signal Transduction
- Abstract
Migration to lymph nodes and secretion of cytokines are critical functions of mature dendritic cells (DCs); however, these 2 functions are not necessarily linked. This is the first report showing that quantitative differences in identical signaling pathways determine DC migration and cytokine secretion. Using different polymerized forms of CD40 ligand, we demonstrate that the strength and persistence of CD40 signaling can induce either function. Induction of monocyte-derived DC (MoDC) migration required a weak and transient CD40 signal, whereas strong and persistent CD40 signaling blocked migration and biased toward cytokine secretion. In contrast to MoDCs, CD40 activation of CD1c+ peripheral blood DCs (PBDCs) induced a nonpersistent, intracellular signaling profile resulting in migratory-type DCs unable to secrete interleukin-12p70 (IL-12p70). Extracellular signal-regulated kinase 1/2 (ERK1/2) and p38K activation synergistically mediated cytokine secretion, whereas migration was enhanced by p38K activation but reduced by persistent ERK1/2 activity. This model of signal strength and persistence also applied when stimulating DCs with intact microbes. Thus, a novel concept emerges in which the type of immune response induced by DCs is tuned by the strength and persistence of DC activating signals.
- Published
- 2004
- Full Text
- View/download PDF
15. Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli.
- Author
-
Jefford M, Schnurr M, Toy T, Masterman KA, Shin A, Beecroft T, Tai TY, Shortman K, Shackleton M, Davis ID, Parente P, Luft T, Chen W, Cebon J, and Maraskovsky E
- Subjects
- Antigens, CD1 metabolism, CD40 Ligand pharmacology, Cell Differentiation drug effects, Cell Differentiation immunology, Cell Division immunology, Cell Movement immunology, Cells, Cultured, Cytokines biosynthesis, Dendritic Cells metabolism, Escherichia coli, Glycoproteins metabolism, Humans, Immunophenotyping, In Vitro Techniques, Inflammation Mediators pharmacology, Lymphocyte Activation immunology, Melanoma immunology, Peptides pharmacology, Stimulation, Chemical, T-Lymphocytes cytology, T-Lymphocytes immunology, Dendritic Cells cytology, Dendritic Cells immunology, Membrane Proteins pharmacology, Monocytes cytology
- Abstract
Dendritic cells (DCs) are a family of leukocytes that initiate T- and B-cell immunity against pathogens. Migration of antigen-loaded DCs from sites of infection into draining lymphoid tissues is fundamental to the priming of T-cell immune responses. In humans, the major peripheral blood DC (PBDC) types, CD1c+ DCs and interleukin 3 receptor-positive (IL-3R+) plasmacytoid DCs, are significantly expanded in vivo with the use of Flt3 ligand (FL). DC-like cells can also be generated from monocyte precursors (MoDCs). A detailed comparison of the functional potential of these types of DCs (in an autologous setting) has yet to be reported. Here, we compared the functional capacity of FL-expanded CD1c+ PBDCs with autologous MoDCs in response to 3 different classes of stimuli: (1) proinflammatory mediators, (2) soluble CD40 ligand trimer (CD40L), and (3) intact bacteria (Escherichia coli). Significant differences in functional capacities were found with respect to changes in phenotype, migratory capacity, cytokine secretion, and T-cell stimulation. MoDCs required specific stimuli for the expression of functions. They responded vigorously to CD40L or E coli, expressing cytokines known to regulate interferon-gamma (IFN-gamma) in T cells (IL-12p70, IL-18, and IL-23), but required prostaglandin E2 (PGE2) during stimulation to migrate to chemokines. In contrast, PBDCs matured in response to minimal stimulation, rapidly acquired migratory function in the absence of PGE2-containing stimuli, and were low cytokine producers. Interestingly, both types of DCs were equivalent with respect to stimulation of allogeneic T-cell proliferation and presentation of peptides to cytotoxic T lymphocyte (CTL) lines. These distinct differences are of particular importance when considering the choice of DC types for clinical applications.
- Published
- 2003
- Full Text
- View/download PDF
16. Clorobiocin biosynthesis in Streptomyces: identification of the halogenase and generation of structural analogs.
- Author
-
Eustáquio AS, Gust B, Luft T, Li SM, Chater KF, and Heide L
- Subjects
- Anti-Bacterial Agents chemistry, Methyltransferases biosynthesis, Mutation, Novobiocin chemistry, Oxidoreductases genetics, Streptomyces enzymology, Structure-Activity Relationship, Anti-Bacterial Agents biosynthesis, Novobiocin analogs & derivatives, Novobiocin biosynthesis, Oxidoreductases metabolism, Streptomyces metabolism
- Abstract
Clorobiocin (clo) and novobiocin (nov) are potent inhibitors of bacterial DNA gyrase. The two substances differ in the substitution pattern at C-8' of the aminocoumarin ring, carrying a chlorine atom or a methyl group, respectively. By gene inactivation, clo-hal was identified as the gene of the halogenase responsible for the introduction of the chlorine atom of clorobiocin. Inactivation of cloZ did not affect clorobiocin formation, showing that this ORF is not essential for clorobiocin biosynthesis. Expression of the methyltransferase gene novO in the clo-hal(-) mutant led to the very efficient formation of a hybrid antibiotic containing a methyl group instead of a chlorine atom at C-8'. Comparison of the antibacterial activity of clorobiocin analogs with -Cl, -H, or -CH(3) at C-8' showed that chlorine leads to 8-fold higher activity than hydrogen and to 2-fold higher activity than a methyl group.
- Published
- 2003
- Full Text
- View/download PDF
17. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets.
- Author
-
Luft T, Jefford M, Luetjens P, Toy T, Hochrein H, Masterman KA, Maliszewski C, Shortman K, Cebon J, and Maraskovsky E
- Subjects
- CD40 Ligand physiology, Cell Differentiation, Cells, Cultured, Chemotaxis, Cyclic AMP metabolism, Cytokines metabolism, Dendritic Cells drug effects, Dinoprostone physiology, Escherichia coli, Humans, Interferon-gamma biosynthesis, Interleukin-2 metabolism, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear physiology, Lymphocyte Activation, Monocytes drug effects, Monocytes physiology, Phenotype, Receptors, CCR7, Receptors, CXCR4 analysis, Receptors, Chemokine analysis, Receptors, Prostaglandin E physiology, Receptors, Prostaglandin E, EP2 Subtype, Receptors, Prostaglandin E, EP4 Subtype, Signal Transduction, T-Lymphocytes immunology, Cell Movement drug effects, Dendritic Cells physiology, Dinoprostone pharmacology
- Abstract
Migration of antigen (Ag)-loaded dendritic cells (DCs) from sites of infection into draining lymphoid tissues is fundamental to the priming of T-cell immune responses. We evaluated monocyte-derived DCs (MoDCs) and peripheral blood DCs (PBDCs) to respond to proinflammatory mediators, CD40L, and intact bacteria. All classes of stimuli induced DC phenotypic maturation. However, for MoDCs, only prostaglandin E(2) (PGE(2))-containing stimuli induced migratory-type DCs. Thus, immature MoDCs that encountered proinflammatory cytokines or CD40L or intact bacteria in the presence of PGE(2) acquired migratory capacity but secreted low levels of cytokines. Conversely, MoDCs that encountered pathogens or CD40L alone become nonmigratory cytokine-secreting cells (proinflammatory type). Interestingly, both migratory- and proinflammatory-type DCs expressed equivalent levels of chemokine receptors, suggesting that the role of PGE(2) was to switch on migratory function. We demonstrate that PGE(2) induces migration via the E-prostanoid 2/E-prostanoid 4 (EP(2)/EP(4)) receptors and the cAMP pathway. Finally, migratory-type MoDCs stimulated T-cell proliferation and predominantly IL-2 secretion, whereas proinflammatory-type MoDCs induced IFN-gamma production. In contrast, CD1b/c(+) PBDC rapidly acquired migratory capacity irrespective of the class of stimulus encountered and secreted low levels of cytokines. This suggests that not all mature stages of DCs are destined to migrate to lymphoid organs and that the sequence in which stimuli are encountered significantly affects which functions are expressed. Thus, certain immature DC subsets recruited from the resting precursor pool may have multiple functional fates that play distinct roles during the induction and effector phases of the immune response. These findings have important implications for the clinical utility of DCs in immunotherapy.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.